JP2024517498A - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
JP2024517498A
JP2024517498A JP2023570456A JP2023570456A JP2024517498A JP 2024517498 A JP2024517498 A JP 2024517498A JP 2023570456 A JP2023570456 A JP 2023570456A JP 2023570456 A JP2023570456 A JP 2023570456A JP 2024517498 A JP2024517498 A JP 2024517498A
Authority
JP
Japan
Prior art keywords
propanamide
hydroxyphenyl
alkyl
halo
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023570456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517498A5 (https=
Inventor
ブライアン リトル，ポウル
ハビエル カセス－トーマス，マヌエル
フールサング キョルビー，マス
ニュケーア，アナス
Original Assignee
インスセンセ アーペーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスセンセ アーペーエス filed Critical インスセンセ アーペーエス
Publication of JP2024517498A publication Critical patent/JP2024517498A/ja
Publication of JP2024517498A5 publication Critical patent/JP2024517498A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Sawing (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Secondary Cells (AREA)
  • Pyridine Compounds (AREA)
JP2023570456A 2021-05-14 2022-05-13 化合物 Pending JP2024517498A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21173972.7A EP4089102A1 (en) 2021-05-14 2021-05-14 Modulators of sortilin activity
EP21173972.7 2021-05-14
PCT/EP2022/063049 WO2022238565A2 (en) 2021-05-14 2022-05-13 Compounds

Publications (2)

Publication Number Publication Date
JP2024517498A true JP2024517498A (ja) 2024-04-22
JP2024517498A5 JP2024517498A5 (https=) 2025-04-22

Family

ID=75936805

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023570456A Pending JP2024517498A (ja) 2021-05-14 2022-05-13 化合物

Country Status (8)

Country Link
US (1) US20240294569A1 (https=)
EP (2) EP4089102A1 (https=)
JP (1) JP2024517498A (https=)
KR (1) KR20240007137A (https=)
CN (1) CN117642416A (https=)
AU (1) AU2022275011A1 (https=)
CA (1) CA3217317A1 (https=)
WO (1) WO2022238565A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4361165A1 (en) * 2022-10-24 2024-05-01 Insusense ApS Modulators of sortilin activity
EP4471047A1 (en) * 2023-05-31 2024-12-04 Insusense ApS Modulators of sortilin activity
JP2026509275A (ja) * 2023-03-07 2026-03-17 ベスパー バイオ アーペーエス ソルチリン修飾剤
EP4428121A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Modulators of sortilin activity
EP4428122A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Sortiline modulators
EP4428124A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Modulators of sortilin activity
EP4719366A1 (en) 2023-05-26 2026-04-08 Bertram Wiedenmann Sortilin inhibitors for treatment of patients with functional neuroendocrine tumors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505063A (ja) * 2013-01-28 2016-02-18 ハー・ルンドベック・アクチエゼルスカベット ソルチリン阻害剤としてのｎ置換された５置換フタルアミド酸
US20160331746A1 (en) * 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake
CN109280075A (zh) * 2017-07-21 2019-01-29 四川海思科制药有限公司 肽酰胺类化合物及其制备方法和在医药上的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW217417B (https=) * 1991-12-04 1993-12-11 Manyu Seiyaku Kk
HUE030465T2 (hu) 2009-05-13 2017-05-29 Antivirális vegyületek
WO2015131100A1 (en) 2014-02-28 2015-09-03 The Scripps Research Institute Ligand-controlled c(sp3)-h arylation and olefination in synthesis of unnatural chiral alpha amino acids
AU2017361155B2 (en) * 2016-11-15 2023-03-30 Tokyo University Of Science Foundation Ras protein degradation inducing molecule and pharmaceutical composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505063A (ja) * 2013-01-28 2016-02-18 ハー・ルンドベック・アクチエゼルスカベット ソルチリン阻害剤としてのｎ置換された５置換フタルアミド酸
US20160331746A1 (en) * 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake
CN109280075A (zh) * 2017-07-21 2019-01-29 四川海思科制药有限公司 肽酰胺类化合物及其制备方法和在医药上的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 222, JPN6026003461, 1994, pages 813 - 824, ISSN: 0005787974 *

Also Published As

Publication number Publication date
CN117642416A (zh) 2024-03-01
KR20240007137A (ko) 2024-01-16
US20240294569A1 (en) 2024-09-05
EP4089102A1 (en) 2022-11-16
WO2022238565A3 (en) 2023-02-23
AU2022275011A1 (en) 2023-11-23
EP4337674A2 (en) 2024-03-20
AU2022275011A9 (en) 2023-11-30
CA3217317A1 (en) 2022-11-17
WO2022238565A2 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
JP2024517498A (ja) 化合物
US20240217922A1 (en) Modulators of sortilin activity
JP2024537619A (ja) 中枢神経系の疾患の処置における使用のためのソルチリンモジュレーターとしての２－アミノ－５，５－ジメチルヘキサン酸誘導体
US20250161321A1 (en) Amino acid based carbamates and/or ureas for the treatment of sortilin dependent diseases
US20240132514A1 (en) Pyridine derivatives as modulators of sortilin activity
EP4428121A1 (en) Modulators of sortilin activity
EP4428124A1 (en) Modulators of sortilin activity
KR20180134401A (ko) 예를 들어 알츠하이머병을 치료하기 위한 선택적 BACE1 억제제로서 N-[3-[2-아미노-5-(1,1-디플루오로에틸)-4,4a,5,7-테트라히드로푸로[3,4-d][1,3]옥사진-7a-일]-4-플루오로-페닐]-5-(트리플루오로메틸)피리딘-2-카르복스아미드 및 그의 (4aR,5S,7aS) 이성질체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203